NCT05838560View on ClinicalTrials.gov

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
SchizophreniaTreatment Resistant DepressionAging, Premature
Interventions
DRUG

Dasatinib

dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

DRUG

quercetin

The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

UConn Health

OTHER

lead

Washington University School of Medicine

OTHER